Victoza and modern insulins boost Novo Nordisk's Q1 and outlook
This article was originally published in Scrip
Executive Summary
Novo Nordisk has reported a 9% increase in sales and a 15% rise in operating profits for the first quarter, as it launched Victoza (liraglutide), the second GLP-1 analogue for type 2 diabetes to reach the market in the US and EU after Lilly/Amylin's Byetta (exenatide). The Danish company also noted the strong performance of its modern insulins franchise, and raised its sales and earnings guidance for the year.